Clinical Trial Agreements With Special Reference To Informed Constent
Author: LawSphereX
Category: General Law
Published:
Updated:
CLINICAL TRIAL AGREEMENTS WITH SPECIAL
REFERENCE TO INFORMED CONSTENT Adv. Pradnya Nakhate, B.A.L.L.B., D.C.L, L.L.M, DES Shri. Navalmal Firodia Law College, Pune
ABSTRACT
Informed Consent: The Heartbeat of CTAs. The concept of informed consent has a historical narrative that can be traced back to important events like the Nuremberg Code and the Declaration of Helsinki. These events played a significant role in shaping research ethics. Over time, the concept has evolved and been influenced by landmark cases and changing ethical frameworks. Informed consent remains a fundamental requirement in clinical trial agreements worldwide, enshrined in regulatory guidelines and institutional protocols. Yet challenges persist in ensuring its comprehensive understanding and implementation across diverse cultural and socioeconomic contexts. The foundation of ethical clinical research lies in informed consent, which represents the intricate equilibrium between scientific progress and the safeguarding of human rights.
It emphasizes the present state of informed consent, elucidates its crucial role in research ethics, and investigates the intricate relationship between medical advancement and patient autonomy. Clinical trial agreements, particularly their legalistic nature, impact participants’ ability to provide informed consent. It seeks to identify areas where agreements hinder understanding and propose potential reforms. A comprehensive review of clinical trial agreements, with a focus on informed consent procedures, identifies areas for improvement and pave the way for more ethical and equitable research practices. Standardized, accessible, and culturally sensitive consent forms; enhanced participant education and involvement; increased transparency and accountability of researchers and sponsors.
The researcher aims to analyse the current state of informed consent in clinical trial agreements, identifying key challenges, and proposing potential reforms will contribute to a more ethical and equitable clinical research landscape. Keywords: Clinical trial agreements, ethical conduct, informed consent, participant rights, participant welfare, transparency.
1) Introduction
Clinical trials serve as the cornerstone of medical research, providing a structured framework for evaluating the safety and efficacy of medical interventions in human subjects. These trials play a vital role in advancing medical knowledge, shaping healthcare policies, and ultimately improving patient outcomes. In essence, clinical trials are systematic investigations designed to assess the effects of interventions such as drugs, devices, procedures, or behavioural therapies on human health. By rigorously testing hypotheses in controlled settings, clinical trials provide valuable data that inform medical decision-making, treatment guidelines, and regulatory approvals.
Given the complexity and ethical considerations inherent in clinical research, various stakeholders, including sponsors, investigators, research institutions, and participants, must navigate a myriad of legal, financial, and operational challenges. This is where clinical trial agreements (CTAs) come into play. Clinical trial agreements are legal contracts that delineate the responsibilities, rights, and obligations of each party involved in a clinical trial. These agreements serve as the foundation for the collaborative relationship between sponsors, investigators, and research institutions, outlining crucial aspects such as protocol adherence, data ownership, publication rights, and financial arrangements. In the context of clinical trials, one of the most fundamental ethical principles is that of informed consent.
Informed consent refers to the process through which individuals voluntarily agree to participate in research after being provided with comprehensive information about the study’s purpose, procedures, risks, and potential benefits. Upholding the principles of autonomy, beneficence, and respect for persons, informed consent ensures that participants make well-informed decisions about their involvement in research, while also safeguarding their rights and welfare. The importance of informed consent in clinical trials cannot be overstated, as it serves as a cornerstone of research ethics and participant protection. It not only empowers individuals to make autonomous decisions about their participation but also fosters transparency, trust, and accountability in the research process.
We will delve into the intricacies of clinical trial agreements, with a particular focus on their interplay with informed consent requirements. By examining the legal, ethical, and practical dimensions of CTAs, we aim to shed light on the complex landscape of clinical research and underscore the importance of upholding ethical standards and participant rights in the pursuit of scientific advancement.
2) Historical Context
The concept of informed consent has emerged from a long and often troubling history of medical experimentation. Prior to the 20th century, research often occurred without participant knowledge or consent, exploiting vulnerable populations like prisoners and the mentally ill. The Tuskegee Syphilis Study (1932-1972), where African American men were denied treatment to study disease progression, stands as a stark reminder of these ethical abuses. The Nuremberg Code (1947), a response to Nazi atrocities, established the first formal requirement for voluntary informed consent in research. Since then, international guidelines like the Declaration of Helsinki (1964) have further refined the principles of informed consent.
2.1 Declaration of Helsinki
The Declaration of Helsinki is a fundamental document in medical research ethics, providing ethical principles for the conduct of research involving human subjects. Originally adopted by the World Medical Association (WMA) in 1964, the Declaration has been revised multiple times to reflect evolving ethical standards and scientific advancements. The most recent version, the 2013 revision, reaffirms the principles outlined in earlier editions while addressing contemporary ethical challenges in research. 1 The Declaration of Helsinki serves as a guiding framework for research ethics committees, regulatory bodies, researchers, and sponsors involved in clinical trials and other research activities. While it is not legally binding, many countries and organizations have incorporated its principles into national laws, regulations, and guidelines governing research conduct.
In India, for example, the Indian Council of Medical Research (ICMR) has adopted the 1WMA, Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects, WORLD MED. ASS’N, available at https://www. wma. net/policies-post/wma-declaration-of-helsinki-ethical-principlesfor-medical-research-involving-human-subjects/, (last visited Mar. 27, 2024). principles of the Declaration of Helsinki in its “National Ethical Guidelines for Biomedical and Health Research Involving Human Participants. ” These guidelines provide ethical standards and procedural requirements for conducting research in India, including informed consent procedures, participant protection measures, and ethical review processes.
Overall, the Declaration of Helsinki plays a crucial role in promoting ethical conduct and protecting the rights and welfare of research participants in clinical trials and other research endeavours worldwide.
2.2 The Nuremberg Code
The Nuremberg Code, established after World War II, outlines ethical principles for human experimentation, aiming to prevent recurring atrocities and establish guidelines for research involving human subjects. 2 Key principles of the Nuremberg Code include: i. Voluntary Consent: The voluntary consent of the subject is absolutely essential. Participants are required to possess the legal ability to provide consent, and such consent must be granted freely, without any form of coercion or undue influence. ii. Avoidance of Unnecessary Harm: The experiment should be designed and conducted to avoid unnecessary physical and mental suffering and injury. iii. Scientific Justification: The experiment should be based on the results of prior animal experimentation and knowledge of the natural history of the disease or other problem under study.
The anticipated benefits of the study should outweigh the risks to participants. 3 iv. Qualified Investigators: The experiment should be conducted by qualified scientists and researchers who are competent to perform the research. 2Trials of War Criminals Before the Nuremberg Military Tribunals Under Control Council Law, Nos. 181–182, vol. 2 (1949). 3The Nuremberg Code, U. S. HOLOCAUST MEMORIAL MUSEUM COLLECTIONS, available at https://collections. ushmm. org/search/catalog/pa1129248, (last visited Apr. 1, 2024). v. Freedom to Withdraw: Participants should have the freedom to withdraw from the study at any time without facing any negative consequences. vi. Informed Consent: Participants should be provided with sufficient information about the nature, purpose, risks, and benefits of the research to make an informed decision about participation.
This includes informing participants of any risks or potential consequences that are reasonably foreseeable. The Nuremberg Code, despite not being legally binding, influenced research ethics and informed consent, leading to its incorporation into laws and regulations, such as the Belmont Report in the United States and the subsequent regulations known as the Common Rule, which govern human subjects research conducted or supported by federal agencies. 4 Overall, the Nuremberg Code serves as a landmark document in the history of research ethics, emphasizing the importance of respect for individuals, voluntary informed consent, and protection of human rights in scientific research.
3) The Constitutional Approach
The Constitution of India provides for the protection of ‘personal liberty’ under Article 21, which also includes protection of personal autonomy. The Supreme Court has held personal liberty and autonomy to include ‘both the negative right not to be subject to interference by others and the positive right of individuals to make decisions about their life, to express themselves and to choose which activities to take part in’.5
4) Clinical Trial Agreements (CTAs)
A clinical trial agreement (CTA) is a legally binding agreement that governs the conduct of a particular study and sets forth the obligations of each party to the agreement. Clinical Trial Agreements (CTAs) govern the relationship between various parties involved in a clinical trial. In India, while not explicitly mandated by law, CTAs are a common practice encouraged by the Drugs Controller General of India’s (DCGI) Good Clinical Practice Guidelines (GCP).
4 Jonathan D. Moreno, Undue Risk
Secret State Experiments on Humans (2001).
5 Anuj Garg v. Hotel Ass’n of India, (2008) 3 S.C.C. 1 (India).
CTAs are formal agreements between several parties involved in a clinical trial: • Sponsor: Typically, a pharmaceutical company funding the research. • Research Site: Hospitals, clinics, or universities conducting the study. • Investigators: Doctors leading the research at the site.
4.1 What are CTAs?
CTAs are legally binding agreements between sponsors (pharmaceutical companies) and research sites (hospitals, universities) in India. • They outline the terms and conditions for conducting a specific clinical trial.
4.2 How CTAs relate to Informed Consent
CTAs often reference the informed consent document, ensuring it adheres to regulatory requirements set forth by the DCGI and ICMR. • They may specify the format, content, and translation requirements for the informed consent document used in the trial. • CTAs can ensure the research site obtains informed consent from participants following the Institutional Ethics Committee (IEC) approved process. • Both CTAs and informed consent documents typically address participant confidentiality and data protection, often aligning with data privacy regulations like the Personal Data Protection Bill, 2021 (pending enactment).
4.3 The Link Between CTAs and Informed Consent in India
While separate documents, CTAs often reference the informed consent process. • They may specify requirements for the content and format of the informed consent document, ensuring it aligns with regulatory guidelines.
CTAs can emphasize the research site’s responsibility to obtain informed consent from participants following the IEC-approved process. 6 • Compensation for trial-related injuries, as mentioned in the informed consent document, might be addressed within the CTA’s financial arrangements section.
4.4 Importance of CTAs in India
Promote clear communication and defined expectations between sponsors and research sites. • Ensure financial transparency and proper allocation of resources for conducting the trial. • Protect the rights and interests of both the sponsor and the research site. • Can indirectly contribute to ethical research practices by emphasizing adherence to informed consent procedures.
5) Informed Consent
The concept of informed consent is often incorrectly perceived as merely obtaining a research participant's signature on the consent form. Informed consent is a cornerstone of ethical medical research in India, particularly in clinical trials. • A document explaining the clinical trial in clear, understandable language. • Presented to potential participants to ensure they fully understand the risks, benefits, and alternatives involved before agreeing to participate. • Obtained voluntarily, with participants having the right to withdraw at any time. • Reviewed and approved by an Institutional Ethics Committee (IEC) before the trial 6 Himani Bhakuni, Informed Consent to Clinical Research in India: A Private Law Remedy, 20 MED. L. INT'L, SAGE JOURNALS (2020), available at Informed consent to clinical research in India: A private law remedy - Himani Bhakuni, 2020 (sagepub.
com), (last visited Apr. 10, 2024). begins. 7
5.1 Importance
Ensures participants understand the risks and benefits of a procedure or clinical trial before agreeing to participate. • Protects participant autonomy and right to self-determination. • Promotes ethical research practices.
5.2 Key Requirements
i. Voluntariness: Consent must be freely given, without coercion or undue influence. ii. Comprehension: Information must be presented in a clear, understandable language, considering literacy levels. Local languages are preferred when possible. iii. Disclosure: The informed consent document should comprehensively explain: • Purpose of the research/procedure • Procedures involved • Potential risks and benefits • Alternative treatment options • Right to withdraw at any time • Confidentiality of data
5.3 Regulation
The Drugs Controller General of India (DCGI) and the ICMR National Ethical Guidelines for Biomedical and Health Research involving Human Participants provide
7 U.S. FOOD & DRUG ADMIN., Informed Consent for Clinical Trials, available at Informed Consent for
Clinical Trials | FDA, (last visited Mar. 30, 2024). the framework for informed consent. • Institutional Ethics Committees (IECs) review and approve informed consent documents before research commences.
5.4 Before enrolling in a clinical trial, the following information must be given to each
potential research subject. 8 i. A statement explaining that the study involves research. ii. An explanation of the objectives of the research. iii. The expected length of time for participation. iv. A description of all the procedures that will be completed during enrolment on the clinical trial. v. Information about all experimental procedures they will be completed during the clinical trial. vi. A description of any predictable risks. vii. Any possible discomforts (e.g., injections, frequency of blood test etc.) that could occur as a result of the research. viii. Any possible benefits that may be expected from the research. ix. Information about any alternative procedures or treatment (if any) that might benefit the research subject. x. A statement describing:
the confidentiality of the data gathered throughout the clinical trial process. • Records that identify the subject will be maintained.
8 Ibid.
the possibility that the FDA may inspect the records.
6) Challenges
Associated with Informed Consent in Clinical Trials (India) While informed consent is a cornerstone of ethical research, implementing it effectively in India presents several challenges. 9 i. Literacy Levels and Language Barriers: India’s population has diverse literacy levels. Complex medical jargon in informed consent documents can be difficult for many to understand. Additionally, translating documents into various local languages is crucial but resource-intensive. ii. Vulnerable Populations: Individuals from economically disadvantaged backgrounds, those with limited literacy, or indigenous communities might be more susceptible to coercion or undue influence when presented with participation opportunities. Extra care needs to be taken to ensure their decisions are truly voluntary. iii.
Compensation: The compensation offered for trial participation can be a significant incentive, particularly for economically disadvantaged individuals. While compensation is acceptable, it’s crucial to ensure it doesn’t outweigh the potential risks or compromise the voluntariness of consent. iv. Lack of Awareness: Limited public understanding of clinical trials and informed consent processes can make it difficult for potential participants to make informed decisions. Educational initiatives are needed to raise awareness and empower communities. v. IEC Workload and Expertise: Institutional Ethics Committees (IECs) are responsible for reviewing informed consent documents. However, workload pressures and limited expertise in some IECs can lead to cursory reviews, potentially missing critical details or inadequacies in the documents.
9 Rashmi Ashish Kadam, Informed Consent Process
A Step Further Towards Making It Meaningful!, NAT’L CTR. FOR BIOTECHNOLOGY INFO., available at Informed consent process: A step further towards making it meaningful! - PMC (nih.gov), (last visited Apr. 4, 2024).
These challenges can lead to situations where participants might not fully comprehend the risks and benefits involved in a clinical trial before consenting. This can have ethical and legal ramifications.
6.1 Here are some potential ways to address these challenges
Develop simplified informed consent documents with visual aids. • Invest in translations into local languages. • Train investigators and research staff on obtaining informed consent effectively, with a focus on vulnerable populations. • Implement clear guidelines on compensation to avoid undue influence. • Promote community engagement and education about clinical trials and informed consent. • Strengthen the role of IECs through capacity building and ensuring adequate expertise for thorough reviews. By acknowledging and addressing these challenges, India can strive towards a more robust informed consent process, fostering ethical clinical research practices and protecting participant rights.
7) Recent Case Studies on Informed Consent Issues
i. Swasthya Adhikar Manch vs. Union of India (2013):10 This case involved a Public Interest Litigation (PIL) filed by an NGO highlighting the exploitation of vulnerable populations in clinical trials conducted in India. The Supreme Court highlighted the need for stricter regulations regarding informed consent and participant safety. This case prompted the formulation of new guidelines for clinical trials in India, emphasizing the importance of robust informed consent procedures. This case spurred stricter regulations, including requiring videotaped informed consent for some trials.
10 Swasthya Adhikar Manch, Indore v. Union of India & Ors., (2013) S.C.C. 900 (India).
ii. Samira Kohli vs Dr. Prabha Manchanda & Anr (2008):11 Here, the court ruled in favor of a patient who experienced adverse effects after participating in a clinical trial. The case underscored the participant’s right to make informed decisions based on complete information. This emphasizes the importance of avoiding coercion or undue influence during the informed consent process, a principle reflected in CTAs. iii. Jaysree Chowdhury & Another vs B. M. Birla Heart Research Center & Another (2010):12 This case dealt with a patient who suffered complications following a cardiac procedure performed as part of a clinical trial. While the specific issue wasn’t informed consent, the court’s emphasis on patient autonomy and the right to information aligns with informed consent principles.
The court emphasized the importance of full disclosure of risks and benefits during the informed consent process. This aligns with the requirement for clear and comprehensive information within CTAs. iv. Kusum Sharma & Ors vs. Union of India & Ors (2013):13 This case involved allegations of unethical practices and inadequate informed consent in a clinical trial of an HPV vaccine. The court emphasized the importance of informed consent and the need for robust IEC oversight. v. Dr. Jacob Puliyel vs. Union of India & Ors (2017):14 This case raised concerns about biased research practices and potential conflicts of interest in clinical trials funded by pharmaceutical companies. It highlighted the importance of transparency and participant safety. These cases demonstrate the ongoing need for vigilance in ensuring informed consent and ethical research practices in India.
8) Conclusion
Informed consent should be regarded as an ongoing and dynamic process, rather than a singular occurrence within the context of a clinical study. The understanding acquired by participants significantly influences their engagement, adherence, and retention throughout the trial.
11 Samira Kohli v. Dr. Prabha Manchanda & Anr., (2008) S.C. 1385 (India).
12 Jaysree Chowdhury & Anr. v. B.M. Birla Heart Research Ctr. & Anr., (2010) C.C. 76 (India).
13 Kusum Sharma & Ors. v. Union of India & Ors., (2014) 6 S.C.C. 287 (India).
14 Dr. Jacob Puliyel v. Union of India & Ors., (2017) 3 S.C.C. 413 (India).
Therefore, it is crucial to perceive the informed consent process as a valuable opportunity to establish effective communication with participants. Researchers conducting clinical trials may encounter numerous challenges during this process, particularly in conveying intricate trialrelated information to participants who possess varying levels of understanding and comprehension. The process of obtaining informed consent can be particularly complex in developing nations such as India, where high illiteracy rates and a wide variety of local languages present significant obstacles. It is crucial for all parties involved in clinical research to engage in collaborative initiatives and adopt innovative approaches that facilitate effective communication of information to trial participants.
Ensuring a valid, meaningful, and comprehensive informed consent process, with a strong focus on patient understanding and comprehension, represents a significant advancement toward fostering "Quality" in the clinical research conducted within our nation.
REFERENCES
1. WMA, Declaration of Helsinki - Ethical Principles for Medical Research Involving
Human Subjects, available at https://www.wma.net/policies-post/wma-declaration-ofhelsinki-ethical-principles-for-medical-research-involving-human-subjects/, last seen on 27/03/2024.
2. Good Clinical Practice (GCP), International ethical and scientific quality standard for
designing, conducting, recording, reporting, and monitoring clinical trials, available at https://www.ich.org/, last seen on 30/03/2024.
3. Informed Consent for Clinical Trials, available at Informed Consent for Clinical Trials
| FDA, last seen on 02/04/2024. 4. Declaration of Helsinki, available at https://www.wma.net/policies-post/wmadeclaration-of-helsinki-ethical-principles-for-medical-research-involving-humansubjects/, last seen at 10/04/2024.
5 Rashmi Ashish Kadam, Informed consent process
A step further towards making it meaningful!, available at Informed consent process: A step further towards making it meaningful! - PMC (nih.gov), last seen on 04/04/2024.
6. The Nuremberg Code, available at
https://collections.ushmm.org/search/catalog/pa1129248, last seen on 01/04/2024.
7 Informed consent to clinical research in India
A private law remedy, Sage Journals, Vol 20, available at Informed consent to clinical research in India: A private law remedy - Himani Bhakuni, 2020 (sagepub.com), last seen on 10/04/2024.